- Home
- DOMO vs MIST Comparison
DOMO vs MIST Comparison
Compare DOMO & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMO | MIST |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 138.2M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DOMO | MIST |
|---|---|---|
| Price | $3.91 | $1.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $10.28 | $8.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | N/A |
| Revenue This Year | $3.41 | $2,915.14 |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.84 | $1.00 |
| 52 Week High | $18.49 | $3.06 |
Technical Indicators
Market Signals| Indicator | DOMO | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 47.70 |
| Support Level | $3.22 | $1.01 |
| Resistance Level | $3.99 | $1.42 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 50.77 | 77.27 |
Price Performance
Historical ComparisonAbout DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.